Erytech Pharma : 2021 : une année décisive
>TRYbeCA1 : verdict attendu pour le T4 - Nous avons eu l’occasion en fin de semaine dernière de faire le point avec le management d’Erytech sur les derniers développements de la société ainsi que sur les principaux jalons cliniques et réglementaires à venir. La publication des résultats finaux de la phase 3 évaluant eryaspase en 2L du cancer du pancréas demeure, selon nous, le principal catalyseur du titre. Un comité indépendant de surveillance (IDMC) avait recommandé...Erytech Pharma is a pharmaceutical company based in France. Co. is primarily engaged in developing cancer therapies that work by starving tumors. Co.'s first product (ERY-ASP), which is in phase III development, provides a therapeutic solution to frail patients with acute leukemia. Co.'s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Co. maintains a production unit located in Lyons with "Pharmaceutical Establishment" status. Co. has also signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.